Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Waldencast Acquires Novaestiq & US Rights to Injectable Hyaluronic Acid Gel Line - Happi
Financial News

Waldencast Acquires Novaestiq & US Rights to Injectable Hyaluronic Acid Gel Line

Saypha products will join the Obagi medical brand.

Waldencast acquired Novaestiq Corp. (Novaestiq), an aesthetic and medical dermatological innovations company. It includes the US rights to the Saypha line of hyaluronic acid (HA) injectable gels.

The strategic acquisition expands Obagi Medical’s offerings beyond US medical-grade skincare.

“We are excited to further diversify Obagi Medical’s portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures through the introduction of the Obagi Medical Saypha ChIQ and MagIQ lines of injectable HA gels,” said Michel Brousset, co-founder and CEO of Waldencast. “Adding proven products into our portfolio increases our addressable market and allows us to deliver solutions for professionals and patients seeking both skincare and aesthetic treatments, all under the trusted Obagi Medical brand.”

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters